RVX.TO : Summary for RESVERLOGIX CORP. - Yahoo Finance

U.S. Markets closed

Resverlogix Corp. (RVX.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
1.77+0.05 (+2.91%)
At close: 3:30 PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.72
Open1.75
Bid1.77 x
Ask1.88 x
Day's Range1.72 - 1.81
52 Week Range1.10 - 2.47
Volume11,047
Avg. Volume45,082
Market Cap186.61M
Beta0.65
PE Ratio (TTM)-6.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group16 days ago

    Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

    Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

  • PR Newswire16 days ago

    Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies

    CALGARY, Nov. 17, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (RVX.TO) today announced the collection of successful data from the New Zealand based Phase 1 PK study with lead drug candidate apabetalone in patients with severe renal impairment. Resverlogix was able to confirm its primary objective of the Phase 1 study by demonstrating that apabetalone treated patients with severe renal impairment have the same favorable PK traits and safety profile as has been observed in previous apabetalone trials.  These results will allow the Company to proceed with more advanced renal impairment and dialysis trials.

  • Zacks Small Cap Research2 months ago

    Resverlogix (RVX.V) October 2016 R&D Update

    On October 13, 2016 Resverlogix Corp. (RVX.TO) held a research and development update for shareholders, investors and analysts in New York City.  Several key opinion leaders (KOLs) and Resverlogix management team members spoke at the event providing an update on the latest thoughts on diabetes, chronic kidney disease (CKD) and how these co-morbidities impact cardiovascular disease.  The discussion and focused on the company’s trials and progress for Resverlogix’s lead compound, apabetalone.